Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

by | Jun 6, 2025 | Clinical Trials | 0 comments

​ Conditions: Metastatic Breast Cancer

Interventions: Other: non-interventional

Sponsors: AstraZeneca

Not yet recruiting Conditions: Metastatic Breast Cancer
Interventions: Other: non-interventional
Sponsors: AstraZeneca
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *